Opendata, web and dolomites

MHT-ImmunoEnhancer SIGNED

Stimuli-Responsive Nanoplatform to Combine Magnetic Hyperthermia with Immunemodulators Delivery for Glioblastoma Treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MHT-ImmunoEnhancer project word cloud

Explore the words cloud of the MHT-ImmunoEnhancer project. It provides you a very rough idea of what is the project "MHT-ImmunoEnhancer" about.

radiotherapy    cpg    spreading    therapy    hyperthermia    conventional    cell    overcome    fu    despite    limited    tolerance    oxide    systemic    ablation    responsive    mdscs    stimuli    depletion    actions    intratumoral    nanocubes    retention    ed    suppressive    appropriate    mdsc    tumours    enzymes    cells    myeloid    urgent    surgery    enhancement    improvements    damage    efficiency    ph    survival    temperature    recurrence    chemotherapeutic    combination    immunosupportive    combine    heating    treatment    hyperthermal    ioncs    iron    effect    poor    stimulus    mht    establishment    immunosuppressive    agent    polymer    inability    gbm    antitumour    human    patient    tme    oligonucleotide    chemotherapy    effectivity    therapies    reactivity    strategy    play    site    dual    platforms    critical    induce    immunoenhancer    immunotherapy    limit    immune    prognosis    suppressor    tumour    consequently    turn    hybrid    appears    local    untreatable    regression    magnetic    extremely    context    thermal    superior    microenvironment    lethal    cytotoxic    release    therapeutic    fever    glioblastoma    fluorouracil   

Project "MHT-ImmunoEnhancer" data sheet

The following table provides information about the project.

Coordinator
FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA 

Organization address
address: VIA MOREGO 30
city: GENOVA
postcode: 16163
website: www.iit.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 183˙473 €
 EC max contribution 183˙473 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2021-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA IT (GENOVA) coordinator 183˙473.00

Map

 Project objective

Glioblastoma (GBM) is one of the most lethal and untreatable human tumours, and is characterized by its extremely poor prognosis. Conventional therapies, including surgery, radiotherapy and chemotherapy, have not resulted in major improvements in the survival, due to high recurrence and tumour spreading. Therefore, there is an urgent need to develop new effective therapies to improve patient survival. The establishment of an immunosuppressive tumour microenvironment (TME) in GBM is known to limit the cytotoxic effects of conventional therapies and in this context, myeloid-derived suppressor cells (MDSCs) play a critical role by promoting immune tolerance, tumour growth and spreading. Hyperthermal therapy in GBM has resulted in improved immune reactivity of tumours, despite this, its effectivity has been limited by its inability to overcome the immunosuppressive TME and induce strong systemic antitumour responses. Consequently, targeting MDSCs in combination with thermal ablation therapies appears to be a very promising strategy. The goal of the MHT-ImmunoEnhancer project is the development of a dual stimuli-responsive hybrid polymer/Iron oxide nanocubes (IONCs) delivery system in order to combine local fever-range Magnetic Hyperthermia (MHT) with MDSC depletion-targeted immunotherapy for intratumoral treatment of GBM. The specific objectives of our strategy are, 1) to exploit the superior heating efficiency of the hybrid polymer/IONCs platforms to induce tumour damage. 2) To turn the immunosuppressive TME into an immunosupportive one, by local delivery of CpG oligonucleotide; along with 5-Fluorouracil (5-FU), a chemotherapeutic agent. 3) To release CpG and 5-FU specifically at the tumour site under the appropriate stimulus (pH or enzymes/temperature), thus enhancing their tumour retention and therapeutic effect. All these actions will result in the reduction of T-cell-suppressive activity of MDSCs, enhancement of antitumour immune response and tumour regression.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MHT-IMMUNOENHANCER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MHT-IMMUNOENHANCER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

PopulistFP (2019)

The Populist Politics of Foreign Policy

Read More  

TheaTheor (2018)

Theorizing the Production of 'Comedia Nueva': The Process of Play Configuration in Spanish Golden Age Theater

Read More  

DNANanoProbes (2019)

Design of light-harvesting DNA-nanoprobes with ratiometric signal amplification for fluorescence imaging of live cells.

Read More